Latest Imatinib Stories
Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug.
Omacetaxine launches different attack on CML that is impervious to other therapies.
SOUTH SAN FRANCISCO, Calif., Dec. 1 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc.
One difficulty with fighting cancer cells is that they are similar in many respects to the body's stem cells.
EAST HANOVER, N.J., Oct. 20 /PRNewswire/ -- Novartis announced today that TasignaÂ® (nilotinib) 200 mg capsules met its primary endpoint in the first head-to-head comparison with the company's groundbreaking drug GleevecÂ® (imatinib mesylate) tablets*.
Investigators have identified a drug that is currently approved to treat certain types of cancer, Gleevec, that could provide the first treatment for scleroderma, a chronic connective tissue disease for which a treatment has remained elusive.
Phase 2 study results of targeted therapy added to chemo.
NEW YORK, Oct. 1 /PRNewswire-USNewswire/ -- The Prix Galien USA committee celebrated members of the science and biotechnology industries last night for the development and discovery of drugs and technologies that improve the human condition.
In new research published in the open-access, peer-reviewed scientific journal PLoS ONE, Dr Patrice Dubreuil and colleagues characterize the pharmacological profile of masitinib (AB1010), a novel tyrosine kinase inhibitor (TKI) that targets the stem cell factor (KIT), PDGFR and Lyn.
NEW YORK, Sept.
- The analysis of literature, focusing on the words and grammar to the exclusion of context or literary merit.